A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy
Objective To evaluate the clinical efficacy and safety of the following different treatment regimens for idiopathic membranous nephropathy（IMN）: modified Ponticelli regimen(MPR, alternating therapy of hormone（Prednisone,Pre） combined with Cyclophosphamide（CTX）, prednisone combined with CTX（Pre/CTX）...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2019-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57910072&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849323615818874880 |
|---|---|
| author | LUO Man-yu LIU Li-hua LIU Sheng-mao ZHANG Dong-mei |
| author_facet | LUO Man-yu LIU Li-hua LIU Sheng-mao ZHANG Dong-mei |
| author_sort | LUO Man-yu |
| collection | DOAJ |
| description | Objective To evaluate the clinical efficacy and safety of the following different treatment regimens for idiopathic membranous nephropathy（IMN）: modified Ponticelli regimen(MPR, alternating therapy of hormone（Prednisone,Pre） combined with Cyclophosphamide（CTX）, prednisone combined with CTX（Pre/CTX） and prednisone combined with Tacrolimus（Pre/TAC）. Methods A total of 67 patients diagnosed with IMN by kidney biopsy from the 2<sup>nd</sup> Hospital of Jilin University were analyzed on their clinical information about urine protein and albumin. Based on the treatment regimens, they were divided into MPR group, Pre/CTX group and Pre/TAC group. All the patients were treated for 6 months. We observed clinical efficacy in the three groups for 3-month and 6-month treatment, and monitored adverse reactions during the treatment course. Results No significant difference was observed at baseline before treatment. After 3-month treatments, in the MPR group, 8（34.7%） of 23 patients reached partly remission and the effectiveness rate is 34.7%; in the Pre/CTX group, 1（4.2%） of 24 patients died, 1（4.2%） reached complete remission, 8（33.3%） reached partly remission and the effectiveness rate is 37.5%; and in the Pre/TAC group, 8（40.0%） of 20 Pre/TAC group patients reached partly remission and the effective rate is 40.0%. The above results in the three groups have no statistical difference. After 6-months treatments, in the MPR group, 1（4.3%） of 23 patients died, 1（4.3%） of the rest 22 patients reached complete remission, 12（52.2%） reached partly remission and the effectiveness rate is 56.5%; in the Pre/CTX group, 2（8.7%） of the rest 23 patients reached complete remission, 17（73.9%） reached partly remission and the effective rate is 82.6%; and in the Pre/TAC group, 1 of 20 patients（5.0%） reached complete remission, 12（60.0%） reached partly remission and the effective rate is 65.0%. The results in the 3 groups have no statistical difference. MPR had less adverse reactions during the treatments. ConclusionsMPR, Pre/CTX and Pre/TAC regimens have comparable effectiveness for IMN; the MPR regimen is characterized by short treatment course and less prednisone accumulation dose, and so may have a high level of safety. |
| format | Article |
| id | doaj-art-f982e3fdff7b473f8bceb94ac176e8b1 |
| institution | Kabale University |
| issn | 1671-2390 |
| language | zho |
| publishDate | 2019-01-01 |
| publisher | Editorial Department of Journal of Clinical Nephrology |
| record_format | Article |
| series | Linchuang shenzangbing zazhi |
| spelling | doaj-art-f982e3fdff7b473f8bceb94ac176e8b12025-08-20T03:48:58ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902019-01-011979880257910072A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathyLUO Man-yuLIU Li-huaLIU Sheng-maoZHANG Dong-meiObjective To evaluate the clinical efficacy and safety of the following different treatment regimens for idiopathic membranous nephropathy（IMN）: modified Ponticelli regimen(MPR, alternating therapy of hormone（Prednisone,Pre） combined with Cyclophosphamide（CTX）, prednisone combined with CTX（Pre/CTX） and prednisone combined with Tacrolimus（Pre/TAC）. Methods A total of 67 patients diagnosed with IMN by kidney biopsy from the 2<sup>nd</sup> Hospital of Jilin University were analyzed on their clinical information about urine protein and albumin. Based on the treatment regimens, they were divided into MPR group, Pre/CTX group and Pre/TAC group. All the patients were treated for 6 months. We observed clinical efficacy in the three groups for 3-month and 6-month treatment, and monitored adverse reactions during the treatment course. Results No significant difference was observed at baseline before treatment. After 3-month treatments, in the MPR group, 8（34.7%） of 23 patients reached partly remission and the effectiveness rate is 34.7%; in the Pre/CTX group, 1（4.2%） of 24 patients died, 1（4.2%） reached complete remission, 8（33.3%） reached partly remission and the effectiveness rate is 37.5%; and in the Pre/TAC group, 8（40.0%） of 20 Pre/TAC group patients reached partly remission and the effective rate is 40.0%. The above results in the three groups have no statistical difference. After 6-months treatments, in the MPR group, 1（4.3%） of 23 patients died, 1（4.3%） of the rest 22 patients reached complete remission, 12（52.2%） reached partly remission and the effectiveness rate is 56.5%; in the Pre/CTX group, 2（8.7%） of the rest 23 patients reached complete remission, 17（73.9%） reached partly remission and the effective rate is 82.6%; and in the Pre/TAC group, 1 of 20 patients（5.0%） reached complete remission, 12（60.0%） reached partly remission and the effective rate is 65.0%. The results in the 3 groups have no statistical difference. MPR had less adverse reactions during the treatments. ConclusionsMPR, Pre/CTX and Pre/TAC regimens have comparable effectiveness for IMN; the MPR regimen is characterized by short treatment course and less prednisone accumulation dose, and so may have a high level of safety.http://www.lcszb.com/thesisDetails?columnId=57910072&Fpath=home&index=0Idiopathic membranous nephropathyGlucocorticoidCyclophosphamideTacrolimus |
| spellingShingle | LUO Man-yu LIU Li-hua LIU Sheng-mao ZHANG Dong-mei A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy Linchuang shenzangbing zazhi Idiopathic membranous nephropathy Glucocorticoid Cyclophosphamide Tacrolimus |
| title | A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy |
| title_full | A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy |
| title_fullStr | A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy |
| title_full_unstemmed | A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy |
| title_short | A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy |
| title_sort | controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy |
| topic | Idiopathic membranous nephropathy Glucocorticoid Cyclophosphamide Tacrolimus |
| url | http://www.lcszb.com/thesisDetails?columnId=57910072&Fpath=home&index=0 |
| work_keys_str_mv | AT luomanyu acontrolledclinicalstudyofefficacyofdifferenttreatmentregimensforidiopathicmembranousnephropathy AT liulihua acontrolledclinicalstudyofefficacyofdifferenttreatmentregimensforidiopathicmembranousnephropathy AT liushengmao acontrolledclinicalstudyofefficacyofdifferenttreatmentregimensforidiopathicmembranousnephropathy AT zhangdongmei acontrolledclinicalstudyofefficacyofdifferenttreatmentregimensforidiopathicmembranousnephropathy AT luomanyu controlledclinicalstudyofefficacyofdifferenttreatmentregimensforidiopathicmembranousnephropathy AT liulihua controlledclinicalstudyofefficacyofdifferenttreatmentregimensforidiopathicmembranousnephropathy AT liushengmao controlledclinicalstudyofefficacyofdifferenttreatmentregimensforidiopathicmembranousnephropathy AT zhangdongmei controlledclinicalstudyofefficacyofdifferenttreatmentregimensforidiopathicmembranousnephropathy |